Applications of CRISPR-Cas9 in Translational Research -

Applications of CRISPR-Cas9 in Translational Research

Jawed Iqbal (Herausgeber)

Buch | Hardcover
300 Seiten
2024
Springer Verlag, Singapore
978-981-16-9799-9 (ISBN)
171,19 inkl. MwSt
This book is a compendium of chapters focusing on the application of CRISPR-Cas 9 in translational research. The initial chapter provides the brief history and basic mechanism of the CRISPR/Cas 9 system and factors influencing its efficacy for treating human diseases and in the field of agriculture, synthetic biology, and environmental sciences. The book also examines the recent advances in the CRISPR-Cas9 technology to improve crop productivity towards achieving the zero hunger goals. Further, the book discusses the recent developments and therapeutic applications of CRISPR-cas9 in gene therapy and the applications of CRISPR/Cas9 in situ correction of disease-causing mutations, loss-of-function mutations, or gain-of-function mutations in various genetic and neuromuscular diseases. It also explores the emerging opportunities of CRISPR-Cas9 in diagnosing and treating infectious diseases caused by bacterial, viral, protozoan, and other parasites. It aims to highlight the current landscape of the applications of CRISPR-Cas9 in the bioengineering and translational research of human diseases. It discusses the applications, mechanisms, strategies for utilizing the role of CRISPR/Cas 9 in engineering genetic circuits and metabolic pathways and metabolic remodeling.

Lastly, the book also reviews various biomedical, legal, and ethical issues related to CRISPR/Cas9 technology for its widespread utilization. It is an invaluable source of information for researchers interested in understanding the translational applications of CRISPR/Cas 9.

Dr. Jawed Iqbal is presently working as a Ramalingaswami Fellow and Assistant Professor in the Multidisciplinary Centre for Advanced Research and Studies (MCARS), Jamia Millia Islamia. Previously, he has done his Ph.D. from the J. N. Medical College, A.M.U. Later on, he carried postdoctoral research from C.M.S., Illinois, U.S.A. He has a patent on the Portable Detection System for sensitive estimation of analytes. His research interest is on understanding the viruses and host innate responses and the applications of CRISPR/Cas 9 in the healthcare system. He has recently developed a mobile phone integrated point of care diagnostic device for detecting COVID-19, named CASSPIT (Cas13 Assisted Saliva-based & Smartphone Integrated Testing), and is currently under transfer to the diagnostic company for manufacturing at the mass level. He has published more than 50 research articles in various peer-reviewed international journals of repute.

Chapter 1: Evolution of CRISPR/Cas 9 as gene editing tool-Introduction chapter a) Brief History., b) Types of CRISPR/Cas system, c) Optimized gene knockout using CRISPR/Cas, d) CRISPR/Cas- based technologies.- Chapter 2: CRISPR/Cas 9 in prokaryotes: beyond adaptive immunity.- Chapter 3: Potential of CRISPR/Cas 9 in environmental and agriculture sciences.- Chapter 4: Clinical applications of CRISPR/Cas9 gene editing.- Chapter 5: CRISPR/Cas9-based strategies against infectious diseases.- Chapter 6: Diagnostics Application of CRISPR/Cas 9.- Chapter 7: CRISPR/Cas9 in biomedical engineering.- Chapter 8: CRISP/Cas: ethical and social issues.- Chapter 9: CRISPR/Cas: Challenges and future opportunities.

Erscheint lt. Verlag 11.12.2024
Zusatzinfo 40 Illustrations, color; 50 Illustrations, black and white; Approx. 300 p. 90 illus., 40 illus. in color.
Verlagsort Singapore
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizin / Pharmazie Studium
Naturwissenschaften Biologie Genetik / Molekularbiologie
Schlagworte Bioengineering • biomedical research • CRISPR/Cas 9 • gene therapy • Inectious disease
ISBN-10 981-16-9799-X / 981169799X
ISBN-13 978-981-16-9799-9 / 9789811697999
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
50 Meilensteine der Genetik

von Jonathan Weitzman; Matthew Weitzman

Buch | Hardcover (2022)
Librero b.v. (Verlag)
9,95